Two hundred years after his seminal publication on the ‘shaking palsy’, what would James Parkinson now make of progress achieved in understanding and treating the disease that bears his name?
Get full access to this article
View all access options for this article.
References
1.
FactorS.A., & WeinerW.J. (ed.) (2008). Parkinson's Disease: Diagnosis and Clinical Management, 2nd edition, 819 pp. New York, NY, USA: Demos Medical Publishing LLC.
2.
CortiO., LesageS., & BriceA. (2011). What genetics tells us about the causes and mechanism of Parkinson's disease. Physiological Reviews91, 1161–1218.
GoetzC.G. (2011). The history of Parkinson's disease: Early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine1, a008862. [doi: 10.1101/cshperspect.a008862]
5.
ShadrinaM.I., SlominskiP.A., & LimborskaS.A. (2010). Molecular mechanisms of pathogenesis of Parkinson's disease. International Reviews of Cell & Molecular Biology281, 229–266.
BeaulieuJ-M., & GainetdinovR.R. (2011). The physiology, signalling, and pharmacology of dopamine receptors. Pharmacological Reviews63, 182–217.
8.
HornykiewiczO. (2010). A brief history of levodopa. Journal of Neurology257, S2, S249–S252.
9.
JennerP. (2013). Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease. Neurological Clinics31, S17–S35.
10.
TieuK. (2011). A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor Perspectives in Medicine1, a009316. [doi: 10.1101/cshperspect.a009316]
11.
MeredithG.E., & RademacherD.J. (2011). MPTP mouse models of Parkinson's disease: An update. Journal of Parkinson's Disease1, 19–33.
12.
XuZ., ChuX., JiangH., SchillingH., ChenS., & FengJ. (2017). Induced dopaminergic neurones: A new promise for Parkinsons disease. Redox Biology11, 606–612.
13.
KyleI. (2017). In situ astrocyte re-programming — simpler cell replacement therapy in PD?Nature Reviews Neurology, 13, 318–319.
14.
FiggeD.A., JaunarajesK.L.E., & StandaertD.G. (2016). Dynamic DNA methylation regulates levodopa-induced dyskinesia. Journal of Neuroscience36, 6514–6524.
15.
WuH., & ZhangY. (2014). Reversing DNA methylation: Mechanisms, genomics, and biological functions. Cell156, 45–68.
ZeissC.J., AlloreH.G., & BeckA.P. (2017). Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's disease. PLoS One12, e017179. [doi: 10.1371/journal.pone.0171790]
18.
HickeyP., & StacyM. (2016). Deep brain stimulation: A paradigm shifting approach to treat Parkinson's disease. Frontiers of Neuroscience10, 173. [doi.org/10.3389/fnins.2016.00173]
19.
BeuterA. (2017). The use of computational models as alternatives to animal models in the development of electrical brain stimulation treatments. ATLA45, 91–99.
20.
TassP.A., QinL., HauptmannC., DoveroS., BezardE., BorodT., & MeissnerW.G. (2011). The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research. Conference Proceedings IEEE Engineering in Medicine & Biology Society2011, 663–666.
21.
ZhongP., HuZ., JiangH., YanZ., & FengJ. (2017). Dopamine induces oscillatory activities in human midbrain neurons with parkin mutations. Cell Reports19, 1033–1044.
22.
GrimmH., & EggelM. (2017). White paper and colourful language: Toward a realistic review of animal research. ATLA45, 101–103.
